TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02044094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for hydromorphone administered via intramuscular injection during each challenge.
Study: NCT00649714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide Capsules 100 mg
Description: 100mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran® Capsules 100 mg
Description: 100mg, single dose fed
Study: NCT01393574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 3 mg for body weight \<40kg, 6 mg for body weight \>40kg, once a day 30-60 minutes before sleep

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
Study: NCT02584972

Intervention type: OTHER
Intervention: no intervention required
Description: no intervention required

Intervention type: OTHER
Intervention: no intervention required
Description: no intervention required
Study: NCT02071472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DP medication reconciliation
Study: NCT03371095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Use of infliximab instead of cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Use of cyclophosphamide
Study: NCT03233009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Daily Defense Serum A
Description: Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
Study: NCT03233009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Daily Defense Serum C
Description: Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Daily Defense Serum G
Description: Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
Study: NCT03197623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LLP2A-ALENDRONATE
Description: A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one time single administration given intravenously over 120 minutes.
Study: NCT03233009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Daily Defense Serum N
Description: Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline Solution Sodium Chloride
Description: Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
Study: NCT01961778

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radio-Frequency Ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Study: NCT01744275

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Description: Placebo
Study: NCT02706015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefaliv® & Placebo
Description: 02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neosaldina® & Placebo
Description: 02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
Study: NCT03286530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment.
Study: NCT02029729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone
Study: NCT04435431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesdopetam
Description: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesdopetam
Description: Oral use
Study: NCT01729273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and Exercise Intervention
Description: Remote Dietary and Exercise Intervention Program
Study: NCT02476019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-FGFR4RX
Description: ISIS-FGFR4RX administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study: NCT00221338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
Study: NCT04825392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
Study: NCT00286104

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics-impregnated ventricular catheter (Bactiseal®)
Description: Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plain ventricular catheter (Codman EDS II/III)
Description: Plain ventricular catheter
Study: NCT04756947

Intervention type: PROCEDURE
Intervention: surgical treatment according to standard indication criteria
Description: internal fixation according to standard indication criteria

Intervention type: PROCEDURE
Intervention: surgical treatment according to standard indication criteria
Description: internal fixation according to standard indication criteria

Intervention type: PROCEDURE
Intervention: conservative treatment according to standard indication criteria
Description: conservative therapy according to standard indication criteria

Intervention type: PROCEDURE
Intervention: conservative treatment according to standard indication criteria
Description: conservative therapy according to standard indication criteria
Study: NCT04596150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072
Description: Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)
Study: NCT02255461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00203229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamotrigine
Description: The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
Study: NCT03790059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H101
Description: Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RFA
Description: Treat the samll HCC with the RFA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Treat the samll HCC with the RFA.
Study: NCT00971139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to an OPPC service
Description: Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
Study: NCT01496469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
Study: NCT01624116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and lifestyle
Description: Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and lifestyle
Description: Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and lifestyle
Description: Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and lifestyle
Description: Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin/ Glimepride
Description: Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin/Sitagliptin
Description: Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
Study: NCT03686293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized breakfast
Description: One tablet of paracetamol (500 mg) and a glass of water (150 mL) is consumed followed by a breakfast consisting of white bread, butter, jam, and juice (300 mL) and
Study: NCT00082407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart
Description: subcutaneous injection, twice daily; titration to target blood glucose level
Study: NCT00091091

Intervention type: OTHER
Intervention: medical chart review
Study: NCT04001569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8186 in combination with paclitaxel
Description: Phase 1b is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D will be determined based on the MTD and toxicity profiles.~In phase 2 part, RP2D from the phase 1b part will be applied.~* AZD8186 ( )mg po bid, 5 days on, 2 days off~* Paclitaxel ( )mg/m² on D1,8,15 every 4 weeks
Study: NCT00091091

Intervention type: OTHER
Intervention: questionnaire administration

Intervention type: PROCEDURE
Intervention: management of therapy complications
Study: NCT03172312

Intervention type: PROCEDURE
Intervention: Different range of thyroid surgery
Description: Observe and record parathyroid status during thyroid surgery

Intervention type: PROCEDURE
Intervention: Different range of thyroid surgery
Description: Observe and record parathyroid status during thyroid surgery
Study: NCT03676244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate implant in defected anterior maxillary esthetic zone
Description: Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment.
Study: NCT04057807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS (0.4 ng/kg)
Study: NCT00797277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM olanzapine
Description: 10mg olanzapine IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM haloperidol plus lorazepam
Description: IM 5 mg haloperidol plus IM 2 mg lorazepam
Study: NCT03477396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Aromatase inhibitor per treating investigator's discretion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04435431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesdopetam
Description: Oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral use
Study: NCT03605758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin is an anti-parasitic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin is an anti-parasitic
Study: NCT01471600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: group drink
Description: group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
Study: NCT03477396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study: NCT04259125

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Evaluation of plasma inflammatory markers including cytokines and micro-RNA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Evaluation of plasma inflammatory markers including cytokines and micro-RNA.

Intervention type: OTHER
Intervention: Survey
Description: Regarding epilepsy and development.
Study: NCT03384368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractured level screws-distraction
Description: four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: fractured level screws-distraction
Description: four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level
Study: NCT03212963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Topical Lotion
Description: Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
Study: NCT05173025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: - Fimasartan group: fimasartan, 60 mg once a day, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: - Fimasartan group: fimasartan, 60 mg once a day, oral administration
Study: NCT02084550

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vaminolac
Description: Vaminolac with an amino acid content corresponding humane breast milk.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
Study: NCT04577469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maldox tablets
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maldox tablets
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-COSPE® tablets
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study: NCT02129439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB012
Description: The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation.
Study: NCT04577469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-COSPE® tablets
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study: NCT02087449

Intervention type: DEVICE
Intervention: E1-Hip Bearing
Description: Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
Study: NCT02123849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study: NCT01321801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Preoperative administration of pregabalin 600mg
Study: NCT03262168

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Programme
Description: Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Programme
Description: Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Programme
Description: Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Programme
Description: Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
Study: NCT03336294

Intervention type: RADIATION
Group type: OTHER
Intervention: SRM P31
Description: All the volunteers involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
Study: NCT01321801

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Preoperative administration of a matching placebo
Study: NCT02129439

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.
Study: NCT04250506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant (ACT-541468) administered as film-coated tablets for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant (ACT-541468) administered as film-coated tablets for oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as tablets for oral use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin administered as film-coated tablets for oral use.